explore -WSS

explore

author：leisure time 2025-09-27 23:32:16 - browse：258

Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： First Opinion Podcast: What happens when kids become caregivers?

WSS

Do more moles mean more problems? Not so, says new study

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

Attacks on the drug industry will lead to fewer breakthroughs

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

ProMED, early warning system on disease outbreaks, in peril

entertainment

explore

knowledge

Bright Health sells Medicare Advantage business to Molina

'Ancient DNA,' 23andMe reveal African American ancestries

DIEP, the 'gold standard' of breast reconstruction, is under threat

Startling documents reveal new facets of Sacklers' opioid empire

How to save PrEP access — and even expand it

iTeos Therapeutics debuts first data on TIGIT

United colonoscopy coverage change 'may cost lives,' doctors say

ER docs worry over extreme heat as a 'mass casualty event'

Trump demands the U.S. pay no more for drugs than other countries … again

Gilgo Beach: Police identify another victim in serial killing investigation

focus

Biohaven protein

The drug industry sees a key ally in the Senate prevail

Focused ultrasound for uterine fibroids: an uphill battle

Prosthetic arm enables patients to feel the objects they grip

Lab trade group sues FDA to halt regulation of lab

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Wikipedia

Wikipedia

entertainment

knowledge